ORIGINAL ARTICLE
Immunohistochemical expression of PARP-1 in triple-negative endometrial cancer – a comparison of different score systems
1
Obstetrics and Gynecology Department with the Oncological Gynecology and Infertility Diagnostics and Treatment Sub-Departments, Multidisciplinary Provincial Hospital, Gorzów Wielkopolski, Poland
2
Department of Pathology, Pomeranian Medical University, Szczecin, Poland
Submission date: 2022-09-01
Acceptance date: 2022-11-17
Publication date: 2023-03-09
Pol J Pathol 2022;73(4):330-337
KEYWORDS
TOPICS
ABSTRACT
Endometrial cancer is the most common malignant neoplasm of the female reproductive system. The number of diagnosed cases is increasing every year. In recent years, the triple-negative phenomenon (TNP) has been identified as one of the determinants of shorter survival in endometrial cancer patients. The aim of the study was to compare the PARP-1 protein expression in triple-negative (TNEC) and non-triple-negative (NTNEC) endometrial cancer patients and determine the relationship between the PARP-1 protein expression in endometrial cancer cells and patient’s overall survival depending on the adopted scale (H-SCORE < 75, H-SCORE < 50, Allred scale).
The study involved 265 patients with histopathologically confirmed endometrial cancer. The patients were divided into 2 groups: patients with TNEC and patients with NTNEC. The study was conducted using a tissue microarray technique. Expression of PARP-1 protein was determined by immunohistochemistry.
Protein expression evaluation was performed using virtual microscopy and the Image Scope computer image analysis system.
The following conclusions were reached: total and individual levels of nuclear or cytoplasmic PARP-1 expression varied with the presence or absence of TNP, and PARP-1 nuclear expression at the 2+ level had a significant effect on the increased risk of death (according to H-SCORE < 75).
The study involved 265 patients with histopathologically confirmed endometrial cancer. The patients were divided into 2 groups: patients with TNEC and patients with NTNEC. The study was conducted using a tissue microarray technique. Expression of PARP-1 protein was determined by immunohistochemistry.
Protein expression evaluation was performed using virtual microscopy and the Image Scope computer image analysis system.
The following conclusions were reached: total and individual levels of nuclear or cytoplasmic PARP-1 expression varied with the presence or absence of TNP, and PARP-1 nuclear expression at the 2+ level had a significant effect on the increased risk of death (according to H-SCORE < 75).
REFERENCES (40)
1.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2021; 0: 1-41.
2.
Kiliañska ZM, ¯o³nierczyk J, Wêsierska-G¹dek J. Biologiczna aktywnoœæ polimerazy poli(ADP-rybozy)-1. Post Hig Med Dosw 2010; 64: 344-363.
3.
Bian X, Gao J, Luo F, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 2018; 37: 341-351.
4.
Philip CA, Laskov I, Beauchamp MC, et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer 2017; 8: 1-11.
5.
Ghabreau L, Roux JP, Frappart PO, et al. Poly(adp-ribose) polymerase-1, a novel partner of progesteron receptors in endometrial cancer and its precursors. Int J Cancer 2004; 109: 317-321.
6.
Janzen DM, Paik DY, Rosales MA, et al. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to poly(ADP-ribose) polymerase (PARP) inhibition in vivo. Mol Cancer Ther 2013; 12: 2917-2928.
7.
Kothari R, Morrison C, Richardson D, et al. The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol Oncol 2010; 118: 172-175.
8.
Voss MA, Gordon N, Maloney S, et al. Tetraspanin CD151 in a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer 2011; 104: 1611-1618.
9.
Xue-Feng J, Qiong-Ian T, Xi-ming S, et al. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma. Pathol Res Pract 2012; 208: 730-735.
10.
Altundag O, Dursun P, Roach EC, et al. Triple negative endometrial cancer may be more sensitive to platinum based chemotherapy. J Buon 2013; 18: 289-295.
11.
Porzio R, Cordini C, Rodolfi AM, et al. Triple negative endometrial cancer: incidence and prognosis in a monoistitutional series of 220 patients. Oncol Lett 2020; 19: 2522-2526.
12.
Bulsa M, Urasiñska E. Triple negative endometrial cancer. Ginekol Pol 2017; 88: 212-214.
13.
McCarty KS, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.
14.
Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2007; 106: 325-333.
15.
Thinke AA, Chang MJ, Fook-Chong S, et al. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-SCORE with pathological parameters. Pathology 2001; 33: 21-25.
16.
Allred D, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
17.
Gottwald L, Kubiak R, Pasz-Walczak G, et al. The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer. Ginekol Pol 2013; 84: 95-101.
18.
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018; 36: 2105-2122.
19.
Bulsa M, Urasiñska E. Triple negative phenomenon in endometrial cancer: recognition criteria and impact on survival. Ginekol Pol 2021.
20.
Bryant HE, Schiltz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of polu(ADP- ribose) polymerase. Nature 2005; 434: 913-917.
21.
Mendes-Pereira AM, Martin SA, Brough R, et al. Sunthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-322.
22.
Magan N, Isaacs RJ, Stowell KM. Treatmet with the PARP- inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells. Anticancer Drugs 2012; 23: 627-637.
23.
Dinkic C, Jahn F, Zygmunt M, et al. PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis. Oncol Lett 2017; 13: 2847-2851.
24.
Barreta A, Sarian LO, Ferracini AC, et al. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis. Hum Pathol 2019; 85: 72-81.
25.
Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
26.
Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta- analysis of individual data for one million adults in 61 prospective studies. Lancet 2002: 360: 1903-1913.
27.
Jagielski L, Jeleñ M, Kobierzycki C, et al. Increase of nuclear expresion of metallothionein I/II in neoplastic transformation of the endometrium. Ginekol Pol 2015; 28: 182-187.
28.
El-Sharkawy SL, Abbas NF, El-Henawy AM, et al. Morphometric and DNA image analysis of endometrial hyperplasia and carcinoma. Appl Immunohistochem Mol Morphol 2017; 25: 32-38.
29.
Elhafey AS, Papadimitriou JC, El-Hakim MS. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, Hyperplastic, and malignant endometrium. Arch Pathol Lab Med 2001; 125: 872-879.
30.
Miller J, Geisler JP, Manahan KJ, et al. Nuclear size, shape, and density in endometrial carcinoma: relationship to survival at over 5 years of follow-up. Does analyzing only cells occupying the G0-G1 peak add useful information? Int J Gynecol Cancer 2004; 14: 138-144.
31.
Sun H, Zeng X, Xu T, et al. Computer-aided diagnosis in histopathological images of the endometrium using a convolutional neural network and attention mechanisms. J Biomed Health Inform 2019; 1: 1-10.
32.
Graham A, Faratian D, Rae F, et al. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 2008; 52: 847-855.
33.
Chen W, Foran D. Advances in cancer tissue microarray technology: towards improved understanding and diagnostics. Anal Chim Acta 2006; 30: 74-81.
34.
Gulmann C, O’Grady A. Tissue microarrays: an overview. Curr Diagn Pathol 2003; 9: 149-154.
35.
Kononen J, Budendorf L, Kallioniemi OP, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
36.
Lugli A, Tornillo L, Mirlacher M, et al. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol 2004; 122: 721-727.
37.
Ganceberg D, Di Leo A, Rouas G, et al. Reliability of the tissue microarray based FOSH for evaluation of the HER-2 oncogene in vreast carcinoma. J Clin Pathol 2002; 55: 315-317.
38.
Chen W, Foran DJ. Advances in cancer tissue microarray technology: towards improved understanding and diagnostics. Anal Chim Acta 2006; 30: 74-81.
39.
Visser N, van der Wurff A, Pijnenborg J, et al. Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer. Virchows Arch 2018; 472: 407-413.
40.
Peres G, Spadoto-Dias D, Bueloni-Dias F, et al. Immunohistochemical expression of hormone receptors, Ki-67, endoglin (CD105), claudins 3 and 4, MMP-2 and -9 in endometrial polyps and endometrial cancer type I. Onco Targets Ther 2018; 11: 3949-3958.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
